Skip to main content
Top
Published in: Journal of Translational Medicine 1/2009

Open Access 01-12-2009 | Research

Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs

Authors: Mark M Aloysius, Alastair J Mc Kechnie, Richard A Robins, Chandan Verma, Jennifer M Eremin, Farzin Farzaneh, Nagy A Habib, Joti Bhalla, Nicola R Hardwick, Sukchai Satthaporn, Thiagarajan Sreenivasan, Mohammed El-Sheemy, Oleg Eremin

Published in: Journal of Translational Medicine | Issue 1/2009

Login to get access

Abstract

Background

Optimal techniques for DC generation for immunotherapy in cancer are yet to be established. Study aims were to evaluate: (i) DC activation/maturation milieu (TNF-α +/- IFN-α) and its effects on CD8+ hTERT-specific T cell responses to class I epitopes (p540 or p865), (ii) CD8+ hTERT-specific T cell responses elicited by vaccination with class I alone or both class I and II epitope (p766 and p672)-pulsed DCs, prepared without IFN-α, (iii) association between circulating T regulatory cells (Tregs) and clinical responses.

Methods

Autologous DCs were generated from 10 patients (HLA-0201) with advanced cancer by culturing CD14+ blood monocytes in the presence of GM-CSF and IL-4 supplemented with TNF-α [DCT] or TNF-α and IFN-α [DCTI]. The capacity of the DCs to induce functional CD8+ T cell responses to hTERT HLA-0201 restricted nonapeptides was assessed by MHC tetramer binding and peptide-specific cytotoxicity. Each DC preparation (DCT or DCTI) was pulsed with only one type of hTERT peptide (p540 or p865) and both preparations were injected into separate lymph node draining regions every 2–3 weeks. This vaccination design enabled comparison of efficacy between DCT and DCTI in generating hTERT peptide specific CD8+ T cells and comparison of class I hTERT peptide (p540 or p865)-loaded DCT with or without class II cognate help (p766 and p672) in 6 patients. T regulatory cells were evaluated in 8 patients.

Results

(i) DCTIs and DCTs, pulsed with hTERT peptides, were comparable (p = 0.45, t-test) in inducing peptide-specific CD8+ T cell responses. (ii) Class II cognate help, significantly enhanced (p < 0.05, t-test) peptide-specific CD8+T cell responses, compared with class I pulsed DCs alone. (iii) Clinical responders had significantly lower (p < 0.05, Mann-Whitney U test) T regs, compared with non-responders. 4/16 patients experienced partial but transient clinical responses during vaccination. Vaccination was well tolerated with minimal toxicity.

Conclusion

Addition of IFN-α to ex vivo monocyte-derived DCs, did not significantly enhance peptide-specific T cell responses in vivo, compared with TNF-α alone. Class II cognate help significantly augments peptide-specific T cell responses. Clinically favourable responses were seen in patients with low levels of circulating T regs.
Appendix
Available only for authorised users
Literature
2.
go back to reference Mellman I, Steinman RM: Dendritic cells: Specialized and regulated antigen processing machines. Cell. 2001, 106: 255-258.PubMed Mellman I, Steinman RM: Dendritic cells: Specialized and regulated antigen processing machines. Cell. 2001, 106: 255-258.PubMed
3.
go back to reference Ardavin C, del Hoyo GM, Martin P, Anjuere F, Arias CF, Marin AR, Ruiz S, Parrillas V, Hernandez H: Origin and differentiation of dendritic cells. Trends In Immunology. 2001, 22: 691-700.PubMed Ardavin C, del Hoyo GM, Martin P, Anjuere F, Arias CF, Marin AR, Ruiz S, Parrillas V, Hernandez H: Origin and differentiation of dendritic cells. Trends In Immunology. 2001, 22: 691-700.PubMed
4.
go back to reference Kim HJ, Yang JS, Woo SS, Kim SK, Yun C-H, Kim KK, Han SH: Lipoteichoic acid and muramyl dipeptide synergistically induce maturation of human dendritic cells and concurrent expression of proinflammatory cytokines. Journal of Leukocyte Biology. 2007, 81: 983-989.PubMed Kim HJ, Yang JS, Woo SS, Kim SK, Yun C-H, Kim KK, Han SH: Lipoteichoic acid and muramyl dipeptide synergistically induce maturation of human dendritic cells and concurrent expression of proinflammatory cytokines. Journal of Leukocyte Biology. 2007, 81: 983-989.PubMed
5.
go back to reference Chen Y, Yang C, Jin N, Xie Z, Tang Y, Fei L, Jia Z, Wu Y: Terminal complement complex C5b-9-treated human monocyte-derived dendritic cells undergo maturation and induce Th1 polarization. European Journal of Immunology. 2007, 37: 167-176.PubMed Chen Y, Yang C, Jin N, Xie Z, Tang Y, Fei L, Jia Z, Wu Y: Terminal complement complex C5b-9-treated human monocyte-derived dendritic cells undergo maturation and induce Th1 polarization. European Journal of Immunology. 2007, 37: 167-176.PubMed
6.
go back to reference Uehori J, Fukase K, Akazawa T, Uematsu S, Akira S, Funami K, Shingai M, Matsumoto M, Azuma I, Toyoshima K: Dendritic cell maturation induced by muramyl dipeptide (MDP) derivatives: monoacylated MDP confers TLR2/TLR4 activation. J Immunol. 2005, 174 (11): 7096-7103.PubMed Uehori J, Fukase K, Akazawa T, Uematsu S, Akira S, Funami K, Shingai M, Matsumoto M, Azuma I, Toyoshima K: Dendritic cell maturation induced by muramyl dipeptide (MDP) derivatives: monoacylated MDP confers TLR2/TLR4 activation. J Immunol. 2005, 174 (11): 7096-7103.PubMed
7.
go back to reference Nakahara S, Tsunoda T, Baba T, Asabe S, Tahara H: Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Research. 2003, 63: 4112-4118.PubMed Nakahara S, Tsunoda T, Baba T, Asabe S, Tahara H: Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Research. 2003, 63: 4112-4118.PubMed
8.
go back to reference Zobywalski A, Javorovic M, Frankenberger B, Pohla H, Kremmer E, Bigalke I, Schendel DJ: Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. Journal of Translational Medicine. 2007, 5: 18-PubMedCentralPubMed Zobywalski A, Javorovic M, Frankenberger B, Pohla H, Kremmer E, Bigalke I, Schendel DJ: Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. Journal of Translational Medicine. 2007, 5: 18-PubMedCentralPubMed
9.
go back to reference Figdor CG, de Vries IJM, Lesterhuis WJ, Melief CJM: Dendritic cell immunotherapy: mapping the way. Nature Medicine. 2004, 10: 475-480.PubMed Figdor CG, de Vries IJM, Lesterhuis WJ, Melief CJM: Dendritic cell immunotherapy: mapping the way. Nature Medicine. 2004, 10: 475-480.PubMed
10.
go back to reference Thurner B, Roder C, Dieckmann D, Heuer M, Kruse M, Glaser A, Keikavoussi P, Kampgen E, Bender A, Schuler G: Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application[erratum appears in J Immunol Methods 1999 Apr 22;224(1–2):211]. Journal of Immunological Methods. 1999, 223: 1-15.PubMed Thurner B, Roder C, Dieckmann D, Heuer M, Kruse M, Glaser A, Keikavoussi P, Kampgen E, Bender A, Schuler G: Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application[erratum appears in J Immunol Methods 1999 Apr 22;224(1–2):211]. Journal of Immunological Methods. 1999, 223: 1-15.PubMed
11.
go back to reference Sallusto F, Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. Journal of Experimental Medicine. 1994, 179: 1109-1118.PubMed Sallusto F, Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. Journal of Experimental Medicine. 1994, 179: 1109-1118.PubMed
12.
go back to reference Grassi F, Dezutter-Dambuyant C, McIlroy D, Jacquet C, Yoneda K, Imamura S, Boumsell L, Schmitt D, Autran B, Debre P, Hosmalin A: Monocyte-derived dendritic cells have a phenotype comparable to that of dermal dendritic cells and display ultrastructural granules distinct from Birbeck granules. Journal of Leukocyte Biology. 1998, 64: 484-493.PubMed Grassi F, Dezutter-Dambuyant C, McIlroy D, Jacquet C, Yoneda K, Imamura S, Boumsell L, Schmitt D, Autran B, Debre P, Hosmalin A: Monocyte-derived dendritic cells have a phenotype comparable to that of dermal dendritic cells and display ultrastructural granules distinct from Birbeck granules. Journal of Leukocyte Biology. 1998, 64: 484-493.PubMed
13.
go back to reference Cella M, Sallusto F, Lanzavecchia A: Origin, maturation and antigen presenting function of dendritic cells. Current Opinion in Immunology. 1997, 9: 10-16.PubMed Cella M, Sallusto F, Lanzavecchia A: Origin, maturation and antigen presenting function of dendritic cells. Current Opinion in Immunology. 1997, 9: 10-16.PubMed
14.
go back to reference Um H-D, Cho Y-H, Kim DK, Shin J-R, Lee Y-J, Choi K-S, Kang J-M, Lee M-G: TNF-alpha suppresses dendritic cell death and the production of reactive oxygen intermediates induced by plasma withdrawal. Experimental Dermatology. 2004, 13: 282-288.PubMed Um H-D, Cho Y-H, Kim DK, Shin J-R, Lee Y-J, Choi K-S, Kang J-M, Lee M-G: TNF-alpha suppresses dendritic cell death and the production of reactive oxygen intermediates induced by plasma withdrawal. Experimental Dermatology. 2004, 13: 282-288.PubMed
15.
go back to reference Iwamoto S, Iwai S-i, Tsujiyama K, Kurahashi C, Takeshita K, Naoe M, Masunaga A, Ogawa Y, Oguchi K, Miyazaki A: TNF-alpha drives human CD14+ monocytes to differentiate into CD70+ dendritic cells evoking Th1 and Th17 responses. Journal of Immunology. 2007, 179: 1449-1457. Iwamoto S, Iwai S-i, Tsujiyama K, Kurahashi C, Takeshita K, Naoe M, Masunaga A, Ogawa Y, Oguchi K, Miyazaki A: TNF-alpha drives human CD14+ monocytes to differentiate into CD70+ dendritic cells evoking Th1 and Th17 responses. Journal of Immunology. 2007, 179: 1449-1457.
16.
go back to reference Keller AM, Groothuis TA, Veraar EAM, Marsman M, de Buy Wenniger LM, Janssen H, Neefjes J, Borst J: Costimulatory ligand CD70 is delivered to the immunological synapse by shared intracellular trafficking with MHC class II molecules. Proceedings of the National Academy of Sciences of the United States of America. 2007, 104: 5989-5994.PubMedCentralPubMed Keller AM, Groothuis TA, Veraar EAM, Marsman M, de Buy Wenniger LM, Janssen H, Neefjes J, Borst J: Costimulatory ligand CD70 is delivered to the immunological synapse by shared intracellular trafficking with MHC class II molecules. Proceedings of the National Academy of Sciences of the United States of America. 2007, 104: 5989-5994.PubMedCentralPubMed
17.
go back to reference Soares H, Waechter H, Glaichenhaus N, Mougneau E, Yagita H, Mizenina O, Dudziak D, Nussenzweig MC, Steinman RM: A subset of dendritic cells induces CD4+ T cells to produce IFN-gamma by an IL-12-independent but CD70-dependent mechanism in vivo. Journal of Experimental Medicine. 2007, 204: 1095-1106.PubMedCentralPubMed Soares H, Waechter H, Glaichenhaus N, Mougneau E, Yagita H, Mizenina O, Dudziak D, Nussenzweig MC, Steinman RM: A subset of dendritic cells induces CD4+ T cells to produce IFN-gamma by an IL-12-independent but CD70-dependent mechanism in vivo. Journal of Experimental Medicine. 2007, 204: 1095-1106.PubMedCentralPubMed
18.
go back to reference Ye Z, Chen Z, Sami A, El-Gayed A, Xiang J: Human dendritic cells engineered to express alpha tumor necrosis factor maintain cellular maturation and T-cell stimulation capacity. Cancer Biotherapy & Radiopharmaceuticals. 2006, 21: 613-622. Ye Z, Chen Z, Sami A, El-Gayed A, Xiang J: Human dendritic cells engineered to express alpha tumor necrosis factor maintain cellular maturation and T-cell stimulation capacity. Cancer Biotherapy & Radiopharmaceuticals. 2006, 21: 613-622.
19.
go back to reference Babatz J, Rollig C, Oelschlagel U, Zhao S, Ehninger G, Schmitz M, Bornhauser M: Large-scale immunomagnetic selection of CD14(+) monocytes to generate dendritic cells for cancer immunotherapy: A phase I study. Journal Of Hematotherapy & Stem Cell Research. 2003, 12: 515-523. Babatz J, Rollig C, Oelschlagel U, Zhao S, Ehninger G, Schmitz M, Bornhauser M: Large-scale immunomagnetic selection of CD14(+) monocytes to generate dendritic cells for cancer immunotherapy: A phase I study. Journal Of Hematotherapy & Stem Cell Research. 2003, 12: 515-523.
20.
go back to reference Bender A, Sapp M, Schuler G, Steinman RM, Bhardwaj N: Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. Journal Of Immunological Methods. 1996, 196: 121-135.PubMed Bender A, Sapp M, Schuler G, Steinman RM, Bhardwaj N: Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. Journal Of Immunological Methods. 1996, 196: 121-135.PubMed
21.
go back to reference Eloranta ML, Sandberg K, RicciardiCastagnoli P, Lindahl M, Alm GV: Production of interferon-alpha/beta by murine dendritic cell lines stimulated by virus and bacteria. Scandinavian Journal Of Immunology. 1997, 46: 235-241.PubMed Eloranta ML, Sandberg K, RicciardiCastagnoli P, Lindahl M, Alm GV: Production of interferon-alpha/beta by murine dendritic cell lines stimulated by virus and bacteria. Scandinavian Journal Of Immunology. 1997, 46: 235-241.PubMed
22.
go back to reference Ferbas JJ, Toso JF, Logar AJ, Navratil JS, Rinaldo CR: Cd4(+) Blood Dendritic Cells are Potent Producers of Ifn-Alpha in Response to In-Vitro Hiv-1 Infection. Journal Of Immunology. 1994, 152: 4649-4662. Ferbas JJ, Toso JF, Logar AJ, Navratil JS, Rinaldo CR: Cd4(+) Blood Dendritic Cells are Potent Producers of Ifn-Alpha in Response to In-Vitro Hiv-1 Infection. Journal Of Immunology. 1994, 152: 4649-4662.
23.
go back to reference Luft T, Pang KC, Thomas E, Hertzog P, Hart DN, Trapani J, Cebon J: Type I IFNs enhance the terminal differentiation of dendritic cells. Journal of Immunology. 1998, 161: 1947-1953. Luft T, Pang KC, Thomas E, Hertzog P, Hart DN, Trapani J, Cebon J: Type I IFNs enhance the terminal differentiation of dendritic cells. Journal of Immunology. 1998, 161: 1947-1953.
24.
go back to reference Paquette RL, Hsu N, Said J, Mohammed M, Rao NP, Shih G, Schiller G, Sawyers C, Glaspy JA: Interferon-alpha induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo[see comment]. Leukemia. 2002, 16: 1484-1489.PubMed Paquette RL, Hsu N, Said J, Mohammed M, Rao NP, Shih G, Schiller G, Sawyers C, Glaspy JA: Interferon-alpha induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo[see comment]. Leukemia. 2002, 16: 1484-1489.PubMed
25.
go back to reference Radvanyi LG, Banerjee A, Weir M, Messner H: Low levels of interferon-alpha induce CD86 (B7.2) expression and accelerates dendritic cell maturation from human peripheral blood mononuclear cells. Scandinavian Journal of Immunology. 1999, 50: 499-509.PubMed Radvanyi LG, Banerjee A, Weir M, Messner H: Low levels of interferon-alpha induce CD86 (B7.2) expression and accelerates dendritic cell maturation from human peripheral blood mononuclear cells. Scandinavian Journal of Immunology. 1999, 50: 499-509.PubMed
26.
go back to reference Santini SM, Lapenta C, Logozzi M, Parlato S, Spada M, Di Pucchio T, Belardelli F: Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. Journal of Experimental Medicine. 2000, 191: 1777-1788.PubMedCentralPubMed Santini SM, Lapenta C, Logozzi M, Parlato S, Spada M, Di Pucchio T, Belardelli F: Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. Journal of Experimental Medicine. 2000, 191: 1777-1788.PubMedCentralPubMed
27.
go back to reference Ferrantini M, Capone I, Belardelli F: Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie. 2007, 89: 884-893.PubMed Ferrantini M, Capone I, Belardelli F: Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie. 2007, 89: 884-893.PubMed
28.
go back to reference Parlato S, Santini SM, Lapenta C, Di Pucchio T, Logozzi M, Spada M, Giammarioli AM, Malorni W, Fais S, Belardelli F: Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood. 2001, 98: 3022-3029.PubMed Parlato S, Santini SM, Lapenta C, Di Pucchio T, Logozzi M, Spada M, Giammarioli AM, Malorni W, Fais S, Belardelli F: Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood. 2001, 98: 3022-3029.PubMed
29.
go back to reference Santodonato L, D'Agostino G, Nisini R, Mariotti S, Monque DM, Spada M, Lattanzi L, Perrone MP, Andreotti M, Belardelli F, Ferrantini M: Monocyte-derived dendritic cells generated after a short-term culture with IFN-alpha and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8+ T cell response. Journal of Immunology. 2003, 170: 5195-5202. Santodonato L, D'Agostino G, Nisini R, Mariotti S, Monque DM, Spada M, Lattanzi L, Perrone MP, Andreotti M, Belardelli F, Ferrantini M: Monocyte-derived dendritic cells generated after a short-term culture with IFN-alpha and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8+ T cell response. Journal of Immunology. 2003, 170: 5195-5202.
30.
go back to reference Luft T, Luetjens P, Hochrein H, Toy T, Masterman KA, Rizkalla M, Maliszewski C, Shortman K, Cebon J, Maraskovsky E: IFN-alpha enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells. International Immunology. 2002, 14: 367-380.PubMed Luft T, Luetjens P, Hochrein H, Toy T, Masterman KA, Rizkalla M, Maliszewski C, Shortman K, Cebon J, Maraskovsky E: IFN-alpha enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells. International Immunology. 2002, 14: 367-380.PubMed
31.
go back to reference McRae BL, Nagai T, Semnani RT, van Seventer JM, van Seventer GA: Interferon-alpha and -beta inhibit the in vitro differentiation of immunocompetent human dendritic cells from CD14(+) precursors. Blood. 2000, 96 (1): 210-217.PubMed McRae BL, Nagai T, Semnani RT, van Seventer JM, van Seventer GA: Interferon-alpha and -beta inhibit the in vitro differentiation of immunocompetent human dendritic cells from CD14(+) precursors. Blood. 2000, 96 (1): 210-217.PubMed
32.
go back to reference Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, Knop J, Enk AH: Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. European Journal of Immunology. 1997, 27: 3135-3142.PubMed Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, Knop J, Enk AH: Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. European Journal of Immunology. 1997, 27: 3135-3142.PubMed
33.
go back to reference Sporri R, Reis e Sousa C: Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function[see comment]. Nature Immunology. 2005, 6: 163-170.PubMed Sporri R, Reis e Sousa C: Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function[see comment]. Nature Immunology. 2005, 6: 163-170.PubMed
34.
go back to reference Morelli AE, Thomson AW: Dendritic cells under the spell of prostaglandins. Trends in Immunology. 2003, 24: 108-111.PubMed Morelli AE, Thomson AW: Dendritic cells under the spell of prostaglandins. Trends in Immunology. 2003, 24: 108-111.PubMed
35.
go back to reference Banerjee DK, Dhodapkar MV, Matayeva E, Steinman RM, Dhodapkar KM: Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood. 2006, 108: 2655-2661.PubMedCentralPubMed Banerjee DK, Dhodapkar MV, Matayeva E, Steinman RM, Dhodapkar KM: Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood. 2006, 108: 2655-2661.PubMedCentralPubMed
36.
go back to reference Satthaporn S, Aloysius MM, Robins RA, Verma C, Chuthapisith S, McKechnie AJ, El-Sheemy M, Vassanasiri W, Valerio D, Clark D: Ex vivo recovery and activation of dysfunctional, anergic, monocyte-derived dendritic cells from patients with operable breast cancer: critical role of IFN-alpha. BMC Immunol. 2008, 9: 32-PubMedCentralPubMed Satthaporn S, Aloysius MM, Robins RA, Verma C, Chuthapisith S, McKechnie AJ, El-Sheemy M, Vassanasiri W, Valerio D, Clark D: Ex vivo recovery and activation of dysfunctional, anergic, monocyte-derived dendritic cells from patients with operable breast cancer: critical role of IFN-alpha. BMC Immunol. 2008, 9: 32-PubMedCentralPubMed
37.
go back to reference Padovan E, Spagnoli GC, Ferrantini M, Heberer M: IFN-alpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells. Journal of Leukocyte Biology. 2002, 71: 669-676.PubMed Padovan E, Spagnoli GC, Ferrantini M, Heberer M: IFN-alpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells. Journal of Leukocyte Biology. 2002, 71: 669-676.PubMed
38.
go back to reference Cella M, Salio M, Sakakibara Y, Langen H, Julkunen I, Lanzavecchia A: Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. Journal of Experimental Medicine. 1999, 189: 821-829.PubMedCentralPubMed Cella M, Salio M, Sakakibara Y, Langen H, Julkunen I, Lanzavecchia A: Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. Journal of Experimental Medicine. 1999, 189: 821-829.PubMedCentralPubMed
39.
go back to reference Carpenter EL, Vonderheide RH: Telomerase-based immunotherapy of cancer. Expert Opinion on Biological Therapy. 2006, 6: 1031-1039.PubMed Carpenter EL, Vonderheide RH: Telomerase-based immunotherapy of cancer. Expert Opinion on Biological Therapy. 2006, 6: 1031-1039.PubMed
40.
go back to reference Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M: Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proceedings of the National Academy of Sciences of the United States of America. 2000, 97: 4796-4801.PubMedCentralPubMed Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M: Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proceedings of the National Academy of Sciences of the United States of America. 2000, 97: 4796-4801.PubMedCentralPubMed
41.
go back to reference Vonderheide RH, Anderson KS, Hahn WC, Butler MO, Schultze JL, Nadler LM: Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clinical Cancer Research. 2001, 7: 3343-3348.PubMed Vonderheide RH, Anderson KS, Hahn WC, Butler MO, Schultze JL, Nadler LM: Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clinical Cancer Research. 2001, 7: 3343-3348.PubMed
42.
go back to reference Vonderheide RH, Domchek SM, Schultze JL, George DJ, Hoar KM, Chen DY, Stephans KF, Masutomi K, Loda M, Xia ZN: Vaccination of cancer patients against telomerase induces functional antitumor CD8+T lymphocytes. Clinical Cancer Research. 2004, 10: 828-839.PubMed Vonderheide RH, Domchek SM, Schultze JL, George DJ, Hoar KM, Chen DY, Stephans KF, Masutomi K, Loda M, Xia ZN: Vaccination of cancer patients against telomerase induces functional antitumor CD8+T lymphocytes. Clinical Cancer Research. 2004, 10: 828-839.PubMed
43.
go back to reference Jonuleit H, Giesecke-Tuettenberg A, Tuting T, Thurner-Schuler B, Stuge TB, Paragnik L, Kandemir A, Lee PP, Schuler G, Knop J, Enk AH: A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer. 2001, 93 (2): 243-251.PubMed Jonuleit H, Giesecke-Tuettenberg A, Tuting T, Thurner-Schuler B, Stuge TB, Paragnik L, Kandemir A, Lee PP, Schuler G, Knop J, Enk AH: A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer. 2001, 93 (2): 243-251.PubMed
44.
go back to reference Sun JC, Williams MA, Bevan MJ: CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection[see comment]. Nature Immunology. 2004, 5: 927-933.PubMedCentralPubMed Sun JC, Williams MA, Bevan MJ: CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection[see comment]. Nature Immunology. 2004, 5: 927-933.PubMedCentralPubMed
45.
go back to reference Smith CM, Wilson NS, Waithman J, Villadangos JA, Carbone FR, Heath WR, Belz GT: Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity[see comment]. Nature Immunology. 2004, 5: 1143-1148.PubMed Smith CM, Wilson NS, Waithman J, Villadangos JA, Carbone FR, Heath WR, Belz GT: Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity[see comment]. Nature Immunology. 2004, 5: 1143-1148.PubMed
46.
go back to reference Castano AP, Mroz P, Wu MX, Hamblin MR: Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model. Proc Natl Acad Sci USA. 2008, 105: 5495-5500.PubMedCentralPubMed Castano AP, Mroz P, Wu MX, Hamblin MR: Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model. Proc Natl Acad Sci USA. 2008, 105: 5495-5500.PubMedCentralPubMed
47.
go back to reference Heier I, Hofgaard PO, Brandtzaeg P, Jahnsen FL, Karlsson M: Depletion of CD4+ CD25+ regulatory T cells inhibits local tumour growth in a mouse model of B cell lymphoma. Clin Exp Immunol. 2008, 152: 381-387.PubMedCentralPubMed Heier I, Hofgaard PO, Brandtzaeg P, Jahnsen FL, Karlsson M: Depletion of CD4+ CD25+ regulatory T cells inhibits local tumour growth in a mouse model of B cell lymphoma. Clin Exp Immunol. 2008, 152: 381-387.PubMedCentralPubMed
48.
go back to reference Sharma S, Dominguez AL, Lustgarten J: High accumulation of T regulatory cells prevents the activation of immune responses in aged animals. J Immunol. 2006, 177: 8348-8355.PubMed Sharma S, Dominguez AL, Lustgarten J: High accumulation of T regulatory cells prevents the activation of immune responses in aged animals. J Immunol. 2006, 177: 8348-8355.PubMed
49.
go back to reference Trzonkowski P, Szmit E, Myliwska J, Myliwski A: CD4+CD25+ T regulatory cells inhibit cytotoxic activity of CTL and NK cells in humans-impact of immunosenescence. Clinical Immunology. 2006, 119: 307-316.PubMed Trzonkowski P, Szmit E, Myliwska J, Myliwski A: CD4+CD25+ T regulatory cells inhibit cytotoxic activity of CTL and NK cells in humans-impact of immunosenescence. Clinical Immunology. 2006, 119: 307-316.PubMed
50.
go back to reference Mahnke K, Schonfeld K, Fondel S, Ring S, Karakhanova S, Wiedemeyer K, Bedke T, Johnson TS, Storn V, Schallenberg S, Enk AH: Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer. 2007, 120: 2723-2733.PubMed Mahnke K, Schonfeld K, Fondel S, Ring S, Karakhanova S, Wiedemeyer K, Bedke T, Johnson TS, Storn V, Schallenberg S, Enk AH: Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer. 2007, 120: 2723-2733.PubMed
51.
go back to reference Lord R, Nair S, Schache A, Spicer J, Somaihah N, Khoo V, Pandha H: Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. Journal of Urology. 2007, 177: 2136-2140. discussion 2140PubMed Lord R, Nair S, Schache A, Spicer J, Somaihah N, Khoo V, Pandha H: Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. Journal of Urology. 2007, 177: 2136-2140. discussion 2140PubMed
52.
go back to reference Schroers R, Shen L, Rollins L, Rooney CM, Slawin K, Sonderstrup G, Huang XF, Chen S-Y: Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes[erratum appears in Clin Cancer Res. 2004 May 15;10(10):3576]. Clinical Cancer Research. 2003, 9: 4743-4755.PubMed Schroers R, Shen L, Rollins L, Rooney CM, Slawin K, Sonderstrup G, Huang XF, Chen S-Y: Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes[erratum appears in Clin Cancer Res. 2004 May 15;10(10):3576]. Clinical Cancer Research. 2003, 9: 4743-4755.PubMed
53.
go back to reference Addison EG, North J, Bakhsh I, Marden C, Haq S, Al-Sarraj S, Malayeri R, Wickremasinghe RG, Davies JK, Lowdell MW: Ligation of CD8 alpha on human natural killer cells prevents activation-induced apoptosis and enhances cytolytic activity. Immunology. 2005, 116: 354-361.PubMedCentralPubMed Addison EG, North J, Bakhsh I, Marden C, Haq S, Al-Sarraj S, Malayeri R, Wickremasinghe RG, Davies JK, Lowdell MW: Ligation of CD8 alpha on human natural killer cells prevents activation-induced apoptosis and enhances cytolytic activity. Immunology. 2005, 116: 354-361.PubMedCentralPubMed
54.
go back to reference Lim HW, Hillsamer P, Banham AH, Kim CH: Cutting edge: direct suppression of B cells by CD4+ CD25+ regulatory T cells. J Immunol. 2005, 175 (7): 4180-4183.PubMed Lim HW, Hillsamer P, Banham AH, Kim CH: Cutting edge: direct suppression of B cells by CD4+ CD25+ regulatory T cells. J Immunol. 2005, 175 (7): 4180-4183.PubMed
55.
go back to reference Fletcher TM: Telomerase: a potential therapeutic target for cancer. Expert Opinion on Therapeutic Targets. 2005, 9: 457-469.PubMed Fletcher TM: Telomerase: a potential therapeutic target for cancer. Expert Opinion on Therapeutic Targets. 2005, 9: 457-469.PubMed
56.
go back to reference Shay JW, Bacchetti S: A survey of telomerase activity in human cancer. European Journal of Cancer. 1997, 33: 787-791.PubMed Shay JW, Bacchetti S: A survey of telomerase activity in human cancer. European Journal of Cancer. 1997, 33: 787-791.PubMed
57.
go back to reference Beatty GL, Vonderheide RH: Telomerase as a universal tumor antigen for cancer vaccines. Expert Rev Vaccines. 2008, 7: 881-887.PubMed Beatty GL, Vonderheide RH: Telomerase as a universal tumor antigen for cancer vaccines. Expert Rev Vaccines. 2008, 7: 881-887.PubMed
58.
go back to reference Nair SKBD, Morse M: Induction of primary carcinoembryonic (CEA) specific cytotoxic T lymphocytes invitro using human dendritic cells transfected with RNA. Nature Biotechnology. 1998, 16: 364-369.PubMed Nair SKBD, Morse M: Induction of primary carcinoembryonic (CEA) specific cytotoxic T lymphocytes invitro using human dendritic cells transfected with RNA. Nature Biotechnology. 1998, 16: 364-369.PubMed
59.
go back to reference Morse MA, Lyerly HK, Gilboa E, Thomas E, Nair SK: Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells. Cancer Res. 1998, 58: 2965-2968.PubMed Morse MA, Lyerly HK, Gilboa E, Thomas E, Nair SK: Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells. Cancer Res. 1998, 58: 2965-2968.PubMed
60.
go back to reference Schaft N, Dorrie J, Thumann P, Beck VE, Muller I, Schultz ES, Kampgen E, Dieckmann D, Schuler G: Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation. J Immunol. 2005, 174: 3087-3097.PubMed Schaft N, Dorrie J, Thumann P, Beck VE, Muller I, Schultz ES, Kampgen E, Dieckmann D, Schuler G: Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation. J Immunol. 2005, 174: 3087-3097.PubMed
61.
go back to reference Busch DH, Kerksiek KM, Pamer EG: Differing roles of inflammation and antigen in T cell proliferation and memory generation. J Immunol. 2000, 164: 4063-4070.PubMed Busch DH, Kerksiek KM, Pamer EG: Differing roles of inflammation and antigen in T cell proliferation and memory generation. J Immunol. 2000, 164: 4063-4070.PubMed
62.
go back to reference Bachmann MF, Beerli RR, Agnellini P, Wolint P, Schwarz K, Oxenius A: Long-lived memory CD8+ T cells are programmed by prolonged antigen exposure and low levels of cellular activation. Eur J Immunol. 2006, 36: 842-854.PubMed Bachmann MF, Beerli RR, Agnellini P, Wolint P, Schwarz K, Oxenius A: Long-lived memory CD8+ T cells are programmed by prolonged antigen exposure and low levels of cellular activation. Eur J Immunol. 2006, 36: 842-854.PubMed
63.
go back to reference Wilson NS, Villadangos JA: Regulation of antigen presentation and cross-presentation in the dendritic cell network: facts, hypothesis, and immunological implications. Adv Immunol. 2005, 86: 241-305.PubMed Wilson NS, Villadangos JA: Regulation of antigen presentation and cross-presentation in the dendritic cell network: facts, hypothesis, and immunological implications. Adv Immunol. 2005, 86: 241-305.PubMed
64.
go back to reference Wang RF, Wang HY: Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells. Nat Biotechnol. 2002, 20: 149-154.PubMed Wang RF, Wang HY: Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells. Nat Biotechnol. 2002, 20: 149-154.PubMed
65.
go back to reference Ludewig B, McCoy K, Pericin M, Ochsenbein AF, Dumrese T, Odermatt B, Toes RE, Melief CJ, Hengartner H, Zinkernagel RM: Rapid peptide turnover and inefficient presentation of exogenous antigen critically limit the activation of self-reactive CTL by dendritic cells. J Immunol. 2001, 166: 3678-3687.PubMed Ludewig B, McCoy K, Pericin M, Ochsenbein AF, Dumrese T, Odermatt B, Toes RE, Melief CJ, Hengartner H, Zinkernagel RM: Rapid peptide turnover and inefficient presentation of exogenous antigen critically limit the activation of self-reactive CTL by dendritic cells. J Immunol. 2001, 166: 3678-3687.PubMed
66.
go back to reference He Y, Zhang J, Mi Z, Robbins P, Falo LD: Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J Immunol. 2005, 174 (6): 3808-3817.PubMed He Y, Zhang J, Mi Z, Robbins P, Falo LD: Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J Immunol. 2005, 174 (6): 3808-3817.PubMed
67.
go back to reference Parkhurst MR, Riley JP, Igarashi T, Li Y, Robbins PF, Rosenberg SA: Immunization of patients with the hTERT:540–548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clinical Cancer Research. 2004, 10: 4688-4698.PubMedCentralPubMed Parkhurst MR, Riley JP, Igarashi T, Li Y, Robbins PF, Rosenberg SA: Immunization of patients with the hTERT:540–548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clinical Cancer Research. 2004, 10: 4688-4698.PubMedCentralPubMed
68.
go back to reference Ayyoub M, Migliaccio M, Guillaume P, Lienard D, Cerottini JC, Romero P, Levy F, Speiser DE, Valmori D: Lack of tumor recognition by hTERT peptide 540–548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing. European Journal of Immunology. 2001, 31: 2642-2651.PubMed Ayyoub M, Migliaccio M, Guillaume P, Lienard D, Cerottini JC, Romero P, Levy F, Speiser DE, Valmori D: Lack of tumor recognition by hTERT peptide 540–548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing. European Journal of Immunology. 2001, 31: 2642-2651.PubMed
69.
go back to reference Purbhoo MA, Li Y, Sutton DH, Brewer JE, Gostick E, Bossi G, Laugel B, Moysey R, Baston E, Liddy N: The HLA A*0201-restricted hTERT540-548 peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor. Molecular Cancer Therapeutics. 2007, 6: 2081-2091.PubMed Purbhoo MA, Li Y, Sutton DH, Brewer JE, Gostick E, Bossi G, Laugel B, Moysey R, Baston E, Liddy N: The HLA A*0201-restricted hTERT540-548 peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor. Molecular Cancer Therapeutics. 2007, 6: 2081-2091.PubMed
70.
go back to reference Brunsvig PF, Aamdal S, Gjertsen MK, Kvalheim G, Markowski-Grimsrud CJ, Sve I, Dyrhaug M, Trachsel S, Moller M, Eriksen JA, Gaudernack G: Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunology, Immunotherapy. 2006, 55: 1553-1564.PubMed Brunsvig PF, Aamdal S, Gjertsen MK, Kvalheim G, Markowski-Grimsrud CJ, Sve I, Dyrhaug M, Trachsel S, Moller M, Eriksen JA, Gaudernack G: Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunology, Immunotherapy. 2006, 55: 1553-1564.PubMed
71.
go back to reference Wenandy L, Sorensen RB, Sengelov L, Svane IM, thor Straten P, Andersen MH: The immunogenicity of the hTERT540-548 peptide in cancer. Clin Cancer Res. 2008, 14: 4-7.PubMed Wenandy L, Sorensen RB, Sengelov L, Svane IM, thor Straten P, Andersen MH: The immunogenicity of the hTERT540-548 peptide in cancer. Clin Cancer Res. 2008, 14: 4-7.PubMed
72.
go back to reference Lapenta C, Santini SM, Logozzi M, Spada M, Andreotti M, Di Pucchio T, Parlato S, Belardelli F: Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha. Journal of Experimental Medicine. 2003, 198: 361-367.PubMedCentralPubMed Lapenta C, Santini SM, Logozzi M, Spada M, Andreotti M, Di Pucchio T, Parlato S, Belardelli F: Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha. Journal of Experimental Medicine. 2003, 198: 361-367.PubMedCentralPubMed
73.
go back to reference Tosi D, Valenti R, Cova A, Sovena G, Huber V, Pilla L, Arienti F, Belardelli F, Parmiani G, Rivoltini L: Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens. J Immunol. 2004, 172 (9): 5363-5370.PubMed Tosi D, Valenti R, Cova A, Sovena G, Huber V, Pilla L, Arienti F, Belardelli F, Parmiani G, Rivoltini L: Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens. J Immunol. 2004, 172 (9): 5363-5370.PubMed
74.
go back to reference Zhou LJTT: CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci USA. 1996, 93: 2588-2592.PubMedCentralPubMed Zhou LJTT: CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci USA. 1996, 93: 2588-2592.PubMedCentralPubMed
75.
go back to reference Filaci G, Fravega M, Setti M, Traverso P, Millo E, Fenoglio D, Negrini S, Ferrera F, Romagnoli A, Basso M: Frequency of telomerase-specific CD8+ T lymphocytes in cancer patients. Blood. 2006, 107: 1505-1512.PubMed Filaci G, Fravega M, Setti M, Traverso P, Millo E, Fenoglio D, Negrini S, Ferrera F, Romagnoli A, Basso M: Frequency of telomerase-specific CD8+ T lymphocytes in cancer patients. Blood. 2006, 107: 1505-1512.PubMed
76.
go back to reference Cortez-Gonzalez X, Zanetti M: Telomerase immunity from bench to bedside: round one. Journal of Translational Medicine. 2007, 5: 12-PubMedCentralPubMed Cortez-Gonzalez X, Zanetti M: Telomerase immunity from bench to bedside: round one. Journal of Translational Medicine. 2007, 5: 12-PubMedCentralPubMed
77.
go back to reference Castellino F, Germain RN: Cooperation between CD4+ and CD8+ T cells: when, where and how. Annual Review of Immunology. 2006, 24: 519-540.PubMed Castellino F, Germain RN: Cooperation between CD4+ and CD8+ T cells: when, where and how. Annual Review of Immunology. 2006, 24: 519-540.PubMed
78.
go back to reference Kumaraguru U, Banerjee K, Rouse BT: In vivo rescue of defective memory CD8(+) T cells by cognate helper T cells. Journal Of Leukocyte Biology. 2005, 78: 879-887.PubMed Kumaraguru U, Banerjee K, Rouse BT: In vivo rescue of defective memory CD8(+) T cells by cognate helper T cells. Journal Of Leukocyte Biology. 2005, 78: 879-887.PubMed
79.
go back to reference Kumaraguru U, Suvas S, Biswas PS, Azkur AK, Rouse BT: Concomitant helper response rescues otherwise low avidity CD8(+) memory CTLs to become efficient effectors in vivo. J Immunol. 2004, 172 (6): 3719-3724.PubMed Kumaraguru U, Suvas S, Biswas PS, Azkur AK, Rouse BT: Concomitant helper response rescues otherwise low avidity CD8(+) memory CTLs to become efficient effectors in vivo. J Immunol. 2004, 172 (6): 3719-3724.PubMed
80.
go back to reference Corthay A, Skovseth DK, Lundin KU, Rosjo E, Omholt H, Hofgaard PO, Haraldsen G, Bogen B: Primary antitumor immune response mediated by CD4(+) T cells. Immunity. 2005, 22: 371-383.PubMed Corthay A, Skovseth DK, Lundin KU, Rosjo E, Omholt H, Hofgaard PO, Haraldsen G, Bogen B: Primary antitumor immune response mediated by CD4(+) T cells. Immunity. 2005, 22: 371-383.PubMed
81.
go back to reference Hokey DA, Larregina AT, Erdos G, Watkins SC, Falo LD: Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity. Cancer Research. 2005, 65: 10059-10067.PubMed Hokey DA, Larregina AT, Erdos G, Watkins SC, Falo LD: Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity. Cancer Research. 2005, 65: 10059-10067.PubMed
82.
go back to reference van Oijen M, Bins A, Elias S, Sein J, Weder P, de Gast G, Mallo H, Gallee M, Van Tinteren H, Schumacher T, Haanen J: On the role of melanoma-specific CD8+ T-cell immunity in disease progression of advanced-stage melanoma patients. Clin Cancer Res. 2004, 10: 4754-4760.PubMed van Oijen M, Bins A, Elias S, Sein J, Weder P, de Gast G, Mallo H, Gallee M, Van Tinteren H, Schumacher T, Haanen J: On the role of melanoma-specific CD8+ T-cell immunity in disease progression of advanced-stage melanoma patients. Clin Cancer Res. 2004, 10: 4754-4760.PubMed
83.
go back to reference Yamshchikov G, Thompson L, Ross WG, Galavotti H, Aquila W, Deacon D, Caldwell J, Patterson JW, Hunt DF, Slingluff CL: Analysis of a natural immune response against tumor antigens in a melanoma survivor: lessons applicable to clinical trial evaluations. Clin Cancer Res. 2001, 7: 909s-916s.PubMed Yamshchikov G, Thompson L, Ross WG, Galavotti H, Aquila W, Deacon D, Caldwell J, Patterson JW, Hunt DF, Slingluff CL: Analysis of a natural immune response against tumor antigens in a melanoma survivor: lessons applicable to clinical trial evaluations. Clin Cancer Res. 2001, 7: 909s-916s.PubMed
84.
go back to reference Romero P, Dunbar PR, Valmori D, Pittet M, Ogg GS, Rimoldi D, Chen JL, Lienard D, Cerottini JC, Cerundolo V: Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med. 1998, 188: 1641-1650.PubMedCentralPubMed Romero P, Dunbar PR, Valmori D, Pittet M, Ogg GS, Rimoldi D, Chen JL, Lienard D, Cerottini JC, Cerundolo V: Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med. 1998, 188: 1641-1650.PubMedCentralPubMed
85.
go back to reference Haanen JBAG, Baars A, Gomez R, Weder P, Smits M, de Gruijl TD, von Blomberg BME, Bloemena E, Scheper RJ, van Ham SM: Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunology, Immunotherapy. 2006, 55: 451-458.PubMed Haanen JBAG, Baars A, Gomez R, Weder P, Smits M, de Gruijl TD, von Blomberg BME, Bloemena E, Scheper RJ, van Ham SM: Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunology, Immunotherapy. 2006, 55: 451-458.PubMed
86.
go back to reference Chen SS, Chen KK, Lin AT, Chang YH, Wu HH, Chang LS: The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis. BJU Int. 2002, 89: 710-713.PubMed Chen SS, Chen KK, Lin AT, Chang YH, Wu HH, Chang LS: The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis. BJU Int. 2002, 89: 710-713.PubMed
87.
go back to reference Stamey TA, Kabalin JN: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients. J Urol. 1989, 141: 1070-1075.PubMed Stamey TA, Kabalin JN: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients. J Urol. 1989, 141: 1070-1075.PubMed
88.
go back to reference Stamey TA, Kabalin JN, Ferrari M: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients. J Urol. 1989, 141: 1084-1087.PubMed Stamey TA, Kabalin JN, Ferrari M: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients. J Urol. 1989, 141: 1084-1087.PubMed
89.
go back to reference Stamey TA, Kabalin JN, Ferrari M, Yang N: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients. J Urol. 1989, 141: 1088-1090.PubMed Stamey TA, Kabalin JN, Ferrari M, Yang N: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients. J Urol. 1989, 141: 1088-1090.PubMed
90.
go back to reference Stamey TA, Kabalin JN, McNeal JE, Johnstone IM, Freiha F, Redwine EA, Yang N: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol. 1989, 141: 1076-1083.PubMed Stamey TA, Kabalin JN, McNeal JE, Johnstone IM, Freiha F, Redwine EA, Yang N: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol. 1989, 141: 1076-1083.PubMed
91.
go back to reference Nosari A, Nichelatti M, De Gasperi A, Nador G, Anghilieri M, Mazza E, Cozzi P, Mancini V, Miqueleiz S, Bettinelli L: Incidence of sepsis in central venous catheter-bearing patients with hematologic malignancies: preliminary results. J Vasc Access. 2004, 5: 168-173.PubMed Nosari A, Nichelatti M, De Gasperi A, Nador G, Anghilieri M, Mazza E, Cozzi P, Mancini V, Miqueleiz S, Bettinelli L: Incidence of sepsis in central venous catheter-bearing patients with hematologic malignancies: preliminary results. J Vasc Access. 2004, 5: 168-173.PubMed
92.
go back to reference Bona RD: Central line thrombosis in patients with cancer. Curr Opin Pulm Med. 2003, 9: 362-366.PubMed Bona RD: Central line thrombosis in patients with cancer. Curr Opin Pulm Med. 2003, 9: 362-366.PubMed
93.
go back to reference Lutsiak MEC, Semnani RT, De Pascalis R, Kashmiri SVS, Schlom J, Sabzevari H: Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 2005, 105: 2862-2868.PubMed Lutsiak MEC, Semnani RT, De Pascalis R, Kashmiri SVS, Schlom J, Sabzevari H: Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 2005, 105: 2862-2868.PubMed
94.
go back to reference Schiavoni G, Mattei F, Di Pucchio T, Santini SM, Bracci L, Belardelli F, Proietti E: Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood. 2000, 95: 2024-2030.PubMed Schiavoni G, Mattei F, Di Pucchio T, Santini SM, Bracci L, Belardelli F, Proietti E: Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood. 2000, 95: 2024-2030.PubMed
95.
go back to reference Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B: Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007, 56 (5): 641-648.PubMed Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B: Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007, 56 (5): 641-648.PubMed
96.
go back to reference Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, Chauffert B, Solary E, Bonnotte B, Martin F: CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. European Journal of Immunology. 2004, 34: 336-344.PubMed Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, Chauffert B, Solary E, Bonnotte B, Martin F: CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. European Journal of Immunology. 2004, 34: 336-344.PubMed
97.
go back to reference Eklund JW, Kuzel TM: Denileukin diftitox: a concise clinical review. Expert Rev Anticancer Ther. 2005, 5: 33-38.PubMed Eklund JW, Kuzel TM: Denileukin diftitox: a concise clinical review. Expert Rev Anticancer Ther. 2005, 5: 33-38.PubMed
98.
go back to reference Frankel AE, Surendranathan A, Black JH, White A, Ganjoo K, Cripe LD: Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia. Cancer. 2006, 106: 2158-2164.PubMed Frankel AE, Surendranathan A, Black JH, White A, Ganjoo K, Cripe LD: Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia. Cancer. 2006, 106: 2158-2164.PubMed
99.
go back to reference Ho VT, Zahrieh D, Hochberg E, Micale E, Levin J, Reynolds C, Steckel S, Cutler C, Fisher DC, Lee SJ: Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood. 2004, 104: 1224-1226.PubMed Ho VT, Zahrieh D, Hochberg E, Micale E, Levin J, Reynolds C, Steckel S, Cutler C, Fisher DC, Lee SJ: Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood. 2004, 104: 1224-1226.PubMed
100.
go back to reference Rasku MA, Clem AL, Telang S, Taft B, Gettings K, Gragg H, Cramer D, Lear SC, McMasters KM, Miller DM, Chesney J: Transient T cell depletion causes regression of melanoma metastases. J Transl Med. 2008, 6: 12-PubMedCentralPubMed Rasku MA, Clem AL, Telang S, Taft B, Gettings K, Gragg H, Cramer D, Lear SC, McMasters KM, Miller DM, Chesney J: Transient T cell depletion causes regression of melanoma metastases. J Transl Med. 2008, 6: 12-PubMedCentralPubMed
101.
go back to reference Zou W: Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006, 6: 295-307.PubMed Zou W: Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006, 6: 295-307.PubMed
Metadata
Title
Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs
Authors
Mark M Aloysius
Alastair J Mc Kechnie
Richard A Robins
Chandan Verma
Jennifer M Eremin
Farzin Farzaneh
Nagy A Habib
Joti Bhalla
Nicola R Hardwick
Sukchai Satthaporn
Thiagarajan Sreenivasan
Mohammed El-Sheemy
Oleg Eremin
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2009
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-7-18

Other articles of this Issue 1/2009

Journal of Translational Medicine 1/2009 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.